MedTrace Logo

To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects

NCT05017168 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-08-11

No results posted yet for this study

Summary

This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.

Conditions

Interventions

DRUG

CT-P63

CT-P63 will be administered

DRUG

Placebo

Placebo-matching CT-P63

Sponsors & Collaborators

Principal Investigators

  • Monika Kiecana, Dr. · Biokinetica S.A.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-11
Primary Completion
2021-11-12
Completion
2022-01-25

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017168 on ClinicalTrials.gov